Navigation Links
Dalton Pharma Services Adds Formulation Development Services
Date:9/21/2009

Dalton Pharma Services is pleased to announce the expansion of its pharmaceutical manufacturing services by adding Formulation Development to its list of integrated capabilities.

Toronto, Ontario (PRWEB) September 21, 2009 -- Dalton Pharma Services is pleased to announce the expansion of its pharmaceutical manufacturing services by adding Formulation Development to its list of integrated capabilities.

This newly created department is comprised of highly experienced and educated teams. Dalton’s analytical, process and formulation scientists are equipped with advanced technology and infrastructure to provide clients with the expertise required to move virtually all types of molecules from development to commercialization in various types of dosage forms. Dosage forms include: sterile and non-sterile liquids, solids, semi-solids and lyophilized formulations (small chemical molecules, proteins and peptides, monoclonal antibodies and high-potency actives).

“Dalton continues to be at the forefront of research, technology and innovation to accelerate our clients’ drug development programs. The addition of Formulation Services to our integrated pharmaceutical development capabilities allows us to offer complete drug development and manufacturing of novel pharmaceutical products. Our investment in state of the art capsule filling technology is one of many examples of how we respond to our clients’ needs. We have also expanded our Analytical Services to serve our formulation development experts and as a result now offer dissolution testing and particle size distribution testing in our FDA compliant, Health Canada approved analytical testing laboratories,” said Peter Pekos, President and CEO of Dalton Pharma Services.

About Dalton Pharma Services:
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.

For further information contact:
Peter Pekos
President & CEO
Dalton Pharma Services
Tel: 416-661-2102
www.dalton.com

###

Read the full story at http://www.prweb.com/releases/2009/09/prweb2915514.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services
2. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
3. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
4. Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008
5. PartsSource President & CEO A. Ray Dalton Named Harvard School of Business Entrepreneur of the Year
6. PartsSource President & CEO A. Ray Dalton Wins Innovation in Business Award
7. Thomson Reuters Launches Thomson Pharma Partnering Forecast
8. With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals(R), Inc. and RealAge.com Launch Effort to Educate Americans on Prevention and Treatment
9. Keryx Biopharmaceuticals, Inc. to Hold Investor/Analyst Day Tomorrow
10. KV Pharmaceutical Divests ANDA for Generic Version of Duac(R)
11. DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dalton Pharma Services Adds Formulation Development Services
(Date:5/4/2016)... ... ... A new collaboration will give more researchers access to the largest and ... leader SAS will provide researchers worldwide with data management and analytics tools to explore ... , The DCRI and SAS share the goal of greater transparency and openness in ...
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star ... created to assist the people of their local community. The agency pledges to ... community leaders. Their hope is to bring awareness to important local causes with ...
(Date:5/4/2016)... Dallas, Texas (PRWEB) , ... May 04, 2016 , ... ... cancer awareness in people across the United States. Dermatologist Dr. Ellen Turner is encouraging ... heed dermatology experts’ advice and focus on skin safety and health now and in ...
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... Dr. ... offering wisdom tooth removal surgery at their office. Wisdom tooth removal, a common dental ... not always problematic, they often are improperly erupted, resulting in risks of complications. By ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nordic Naturals ... cellular and metabolic health. This synergistic combination of omega-3 fatty acids and potent ... 150 mg of reduced glutathione and 200 mg of N-Acetylcysteine (NAC). , ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- According to market research "Global Magnetic ... Demand Forecast to 2022 - Industry Insights by Architecture ... High Field, Low to Mid Field, and Ultra High ... Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" P&S ... was valued at $5,351.7 million in 2015, and it ...
(Date:5/3/2016)... May 3, 2016 ... dass sie einen entscheidenden Meilenstein durch diese ... Aufruf zum Handeln, um Patientenresultate  bei Verdauungs- ... zu Fortschritten im Verständnis der Hepatischen Enzephalopathie ... Bewusstsein für Hepatische Enzephalopathie in der Öffentlichkeit ...
(Date:5/2/2016)...  Celsion Corporation (NASDAQ: CLSN ), an ... the first cohort of patients in its Phase ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... the first three patients dosed, GEN-1 plus standard ...
Breaking Medicine Technology: